Phase 2 N=12 Peginterferon and TIL Therapy for Metastatic Melanoma
Metastatic Melanoma
Primary: Number of Participants With Adverse Events/Serious Adverse Events — 12; 12; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI
Prostate Cancer
Primary: Number of Patients With Primary Lesions Detected — 14 Participants
Phase 2 N=152 Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
Sjogren's Syndrome
Primary: Percentage of Participants Fulfilling Protocol-Specified Response Criteria at Week 12, as Compared to Baseline — 42.9; 43.2; 35.1; 26.5 percentage of participants…
Phase 2 N=32 Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
Bladder Cancer
Primary: Percentage of Participants Without Recurrence (Recurrence-free Survival (RFS)) With Bacillus Calmette-Guerin (BCG) + PANVAC Compared With BCG Alone at 6 and 12 Months…
Phase 2 N=35 PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer
Metastatic Malignant Neoplasm in the Brain · Recurrent Non-Small Cell Lung Carcinoma · Stage IIA Non-Small Cell Lung Carcinoma
Primary: Metabolic Response of All Pulmonary Lesions and Thoracic Lymph Nodes — 24 Participants
Phase 2 N=13 Efavirenz and Ritonavir on Human Brain P-Glycoprotein
Drug Effects
Primary: Cerebral [11C]dLop Distribution Volume
Phase 2 N=146 Peanut Oral Immunotherapy in Children
Peanut Hypersensitivity
Primary: Percentage of Participants Desensitized to Peanut Protein After 134 Weeks of Oral Immunotherapy (OIT) — 71; 2 Percentage of Participants — p=<0.0001
Phase 2 N=12 A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects
Hepatitis B
Primary: Part 1: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Indicated Time Points — -3.67; 3.00; 0.50; -5.33 Millimeters of…
Phase 2 N=46 T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Acute Lymphoblastic Leukemia · Non Hodgkins Lymphoma · Myelodysplastic Syndrome
Primary: Engraftment Rate After Transplant — 100; 100 percentage of participants
Phase 2 N=37 BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer
Primary: Number of Participants With 8-week Progression-Free Survival (i.e. Disease Control Rate) Stratified by Cancer Mutation Type — 11; 1; 0; 1 participants
Phase 2 N=63 Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemia
Primary: Overall Response Rate — 57 Participants
Phase 2 N=76 A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function
Hypertension
Primary: Change in Small Artery Elasticity — 2.4; 1.0; 0.4 (ml/mmHg × 100)
Phase 2 N=1 Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
Ameloblastoma · BRAF Gene Mutation
Primary: Tumor Response — 0; 0; 0; 0 Participants
Phase 2 N=16 Bioavailability of Amoxicillin Dissolved in Human Milk
Healthy
Primary: Area Under the Curve to Time Infinity (AUC to Time Infinity) — 1394.1; 1477.2 mcg*min/mL
Phase 2 N=22 Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study
Chemo Brain · Chemotherapy-related Cognitive Impairment · Chemo Fog
Primary: Change in the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) PCI Scale — 7.00; 11.55; 16.80; 16.64 units on a scale — p==0.41